Evidence map›Paper›PMID 37391439›Full record

ArticleScientific reports2023

Growth, allergen profile and microbiome studies in Dermatophagoides pteronyssinus cultures.

D Calzada, L Martín-López, Jerónimo Carnés

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Update on HDM Allergy: Principal Changes over the Years.International journal of molecular sciences · 2025
    Review
  3. A novelmSphere · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

D CalzadaR&D Unit, Allergy & Immunology, LETI Pharma S.L.U., Calle del Sol nº 5, Tres Cantos, 28760, Madrid, Spain.
L Martín-LópezR&D Unit, Allergy & Immunology, LETI Pharma S.L.U., Calle del Sol nº 5, Tres Cantos, 28760, Madrid, Spain.
Jerónimo CarnésR&D Unit, Allergy & Immunology, LETI Pharma S.L.U., Calle del Sol nº 5, Tres Cantos, 28760, Madrid, Spain. jcarnes@leti.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mites are mass-cultured to manufacture allergen extracts for allergy diagnostics and therapeutic treatment. This study focused on characterizing the growth, the allergen profile, and the microbiome of Dermatophagoides pteronyssinus cultures. Mite population, protein profile, total protein content and major allergen levels (Der p 1, Der p 2, Der p 23) were monitored at different times of three independent cultures. The allergenicity was studied by immunoblot using a pool of sera from allergic patients. Mite microbiome was characterized by sequencing the 16S rRNA gene from 600 adult mites from the last day of the culture. Endotoxin content was also analyzed. The cultures had a fast and unrelenting evolution. Mite density, total protein content, major allergen levels and the allergenicity were increased progressively during the cultures. Regarding the microbiome studies, the results confirm the presence of non-pathogenic bacteria, being firmicutes and actinobacteria the most common bacterial taxa, with a very low content of Gram-negative bacteria and endotoxin content. The allergenicity and levels of the main allergens in the mite cultures are objective methods useful to monitor the mite culture that help to produce standardized allergen extracts. The high presence of Gram-positive bacteria found limits the possibility for vaccine contamination by bacterial endotoxins.

Indexed as

HypersensitivityMicrobiotaAdultAllergensAnimalsDermatophagoides pteronyssinusEndotoxinsHumansRNA, Ribosomal, 16SAllergensEndotoxinsRNA, Ribosomal, 16S

Identifiers

PMID37391439
PMCPMC10313659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.